Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0344307 (analgesia)
 28,200 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The research on endogenous opioid is only a decade old but the considerable number and the variety of studies devoted to this subject suggest that these neuropeptides might play a pivotal role in various biological functions. The most abundant opioid peptides enkephalins are synthesized as large precursors. They bind to several classes of receptors as mu and delta types and are degraded by specific enzymes (aminopeptidase M, enkephalinase, dipeptidylaminopeptidase) belonging to the group of metallopeptidases. The analysis of the functions of the enkephalinergic system can now be investigated by using recently designed selective mu (DAGO, TRIMU 5), delta (DTLET, DEPDPE), kappa (U 50, 488) agonists or antagonists (ICI 174, 864 for the delta type) and kelatorphan a complete inhibitor of enkephalin metabolism. The former probes were obtained by a rational approach based on the conformational adaptability of the endogenous peptides while inhibitors of enkephalin degrading enzymes were designed by taking into account crystallographic data on metallopeptidases. mu and delta receptors present distinct distributions in the brain. Enkephalinase visualized by autoradiography seems to be closely associated with opioid receptors. Pain control could be insured in brain structures by mu receptor-stimulation whereas both mu and delta types might be involved at the level of the spinal cord. In both cases, a "physiological" analgesia is produced by kelatorphan.
 ...
PMID:[The pharmacology of various classes of cerebral opioid receptors]. 302 30

Neutral endopeptidase (EC3.4.24.11, NEP, enkephalinase) is a zinc-metalloendopeptidase, cleaving a variety of substrates like enkephalins, substance P, and bradykinin. In the brain, NEP is a key enzyme in the degradation of enkephalins. Pharmacological inhibition of NEP-activity causes analgesia resulting from enhanced extracellular enkephalin concentrations. Recently, transgenic mice lacking the enzyme NEP have been developed (Lu, 1995). The present study was designed to investigate the nociceptive behavior of these NEP-knockout mice. Interestingly, NEP-deficient mice did not respond with decreased pain perception, but exhibited hyperalgesia in the hot-plate jump, warm-water tail-withdrawal, and mostnotablyin theacetic-acid writhing test. Inhibition of aminopeptidase N by bestatin reduced writhing in both strains, whereas NEP-inhibition by thiorphan reduced writhing selectively in wild-type mice. Naloxone increased writhing in wild-type but not in knockouts, whereas the bradykinin B2-receptor antagonist HOE140 reduced writhing selectively in NEP-knockouts. Similarly, the nitric oxide synthase inhibitor L-NAME reduced writhing in NEP-knockouts. These results indicate that genetic elimination of NEP, in contrast to pharmacological inhibition, leads to bradykinin-induced hyperalgesia instead of enkephalin-mediated analgesia. Nitric oxide (NO) is suggested to be involved in this process.
 ...
PMID:Neutral endopeptidase knockout induces hyperalgesia in a model of visceral pain, an effect related to bradykinin and nitric oxide. 1193 42